- 期刊
A Randomized Controlled Meta-analysis on Sunitinib and Pazopanib in the Treatment of Renal Cancer
摘要
Background: RCC (viz. Renal cell carcinoma) takes up ninety percent of cancers of kidney. It consists of about three percent of the entire novel cases of adults. The kidney cancer is at the eighth place of the men's cancer frequently seen in Britain and the fourteenth of women's. VEGF (viz. vascular endothelial growth factor) refers to a critical pathway for angiogenesis of tumours and is important for the RCC progression, namely the renal cell carcinoma. Normal first-line VEGF-TT starts at either pazopanib or sunitinib. The data of trials in clinics found noninferiority of pazopanib in OS (namely, overall survival), in comparison with sunitinib being the priority treatment regarding mRCC (viz. metastatic renal cell carcinoma). A rationale for clinics and pharmacokinetics was alternative or non-classic. It dosed schedules integrating sunitinib. It encouraged to investigate of the results of the two drugs. Methods: The trials in clinics comparing the two drugs among the patients who had cancer of renal by 2019 were identified by a systematic review. The keywords including ＂sunitinib＂, ＂renal cancer＂ and ＂pazopanib＂ as well as corresponding combinations were searched in the databases, namely Cochrane, Web of Science, Pubmed, and EMBase. Regarding the first and second results collected from the included works, a systematic comparison was adopted as a network meta-analysis comparing the two drugs. Results: Eleven studies, consisting of 4784 patients, were involved in the present network meta-analysis. Significance was found between sunitinib and pazopanib regarding critical effectiveness and the outcomes of security. For example, there are toxicity-based dose reduction, overall survival, and proportions of the patients who undertook interventions regarding harmful events. The pazopanib had better effectiveness than sunitinib.
參考文獻
延伸閱讀
- 陳健文（2006）。A Case-Control Study for Investigating the Effect of Over-The-Counter (OTC) Medications on Renal Function〔碩士論文，國立臺灣大學〕。華藝線上圖書館。https://doi.org/10.6342/NTU.2006.02827
- 許軒之、陳鴻華、王重榮、黃英彥、張家駱、熊敬業、陳惠君（1999）。Adjuvant Postoperative Radiotherapy of Rectal Cancer: An Analysts of Treatment Results and Prognostic Factors。放射治療與腫瘤學，6(3)，179-186。https://doi.org/10.6316/TRO/199906(3)179
- 馮文瑋（2005）。The Relationship between Immunosuppressive Agents of Renal Transplant and Associated Malignant Tumors〔碩士論文，高雄醫學大學〕。華藝線上圖書館。https://www.airitilibrary.com/Article/Detail?DocID=U0011-2903200614025261
- Cianchetti, M., & Amichetti, M. (2012). Sinonasal Malignancies and Charged Particle Radiation Treatment: A Systematic Literature Review. International Journal of Otolaryngology, 2012(), 115-129. https://doi.org/10.1155/2012/325891
- Liu, L. Y. M., Lin, P. L., Liao, F. C., Lin, S. I., Chiou, W. R., Wu, Y. J., & Lee, Y. H. (2019). Effect of Radiofrequency-Based Renal Denervation: The Impact of Unplanned Medication Change from a Systematic Review and Meta-Analysis. Acta Cardiologica Sinica, 35(2), 144-152. https://doi.org/10.6515/ACS.201903_35(2).20181231A